» Articles » PMID: 36631448

TP73 Isoform-specific Disruption Reveals a Critical Role of TAp73beta in Growth Suppression and Inflammatory Response

Overview
Journal Cell Death Dis
Date 2023 Jan 11
PMID 36631448
Authors
Affiliations
Soon will be listed here.
Abstract

TP73 is expressed as multiple N- and C-terminal isoforms through two separate promoters or alternative splicing. While N-terminal p73 isoforms have been well studied, very little is known about p73 C-terminal isoforms. Thus, CRISPR was used to delete TP73 Exon13 (E13-KO) to induce p73α to p73β isoform switch. We showed that E13-KO led to decreased cell proliferation and migration and sensitized cells to ferroptosis, which can be reverted by knockdown of TAp73β in E13-KO cells. To understand the biological function of p73β in vivo, we generated a mouse model in that the Trp73 E13 was deleted by CRISPR. We showed that p73α to p73β isoform switch led to increased cellular senescence in mouse embryonic fibroblasts. We also showed that E13-deficient mice exhibited shorter life span and were prone to spontaneous tumors, chronic inflammation and liver steatosis as compared to WT mice. Additionally, we found that the incidence of chronic inflammation and liver steatosis was higher in E13-deficient mice than that in Trp73-deficient mice, suggesting that p73β is a strong inducer of inflammatory response. Mechanistically, we showed that TAp73β was able to induce cysteine dioxygenase 1 (CDO-1), leading to cysteine depletion and subsequently, enhanced ferroptosis and growth suppression. Conversely, knockdown of CDO-1 was able to alleviate the growth suppression and ferroptosis in E13-KO cells. Together, our data suggest that at a physiologically relevant level, TAp73β is a strong inducer of growth suppression but insufficient to compensate for loss of TAp73α in tumor suppression due to aberrant induction of inflammatory response and liver steatosis.

Citing Articles

Intron retention as an excellent marker for diagnosing depression and for discovering new potential pathways for drug intervention.

Okada N, Oshima K, Maruko A, Sekine M, Ito N, Wakasugi A Front Psychiatry. 2024; 15:1450708.

PMID: 39364384 PMC: 11446786. DOI: 10.3389/fpsyt.2024.1450708.


Sex-specific epigenetic signatures of circulating urate and its increase after BCG vaccination.

Liu Z, Crisan T, Qi C, Gupta M, Liu X, Moorlag S Res Sq. 2024; .

PMID: 39108482 PMC: 11302698. DOI: 10.21203/rs.3.rs-4498597/v1.

References
1.
Nemajerova A, Amelio I, Gebel J, Dotsch V, Melino G, Moll U . Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism. Cell Death Differ. 2017; 25(1):144-153. PMC: 5729534. DOI: 10.1038/cdd.2017.178. View

2.
Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Furst K . DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell. 2013; 24(4):512-27. DOI: 10.1016/j.ccr.2013.08.023. View

3.
Wei J, Zaika E, Zaika A . p53 Family: Role of Protein Isoforms in Human Cancer. J Nucleic Acids. 2011; 2012:687359. PMC: 3191818. DOI: 10.1155/2012/687359. View

4.
Dohn M, Zhang S, Chen X . p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene. 2001; 20(25):3193-205. DOI: 10.1038/sj.onc.1204427. View

5.
Iscan E, Ekin U, Yildiz G, Oz O, Keles U, Suner A . TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation. Cancers (Basel). 2021; 13(4). PMC: 7918882. DOI: 10.3390/cancers13040783. View